Log in to save to my catalogue

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation:...

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation:...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04989148v1

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Publication information

Publisher

Elsevier Ltd

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs.
We conducted a randomised, open-label phase...

Alternative Titles

Full title

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04989148v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04989148v1

Other Identifiers

ISSN

0140-6736,1474-547X

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(23)00221-0

How to access this item